vs
Apellis Pharmaceuticals, Inc.（APLS）与Terreno Realty Corp（TRNO）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Terreno Realty Corp的1.5倍（$199.9M vs $137.5M），Terreno Realty Corp净利率更高（115.1% vs -29.5%，领先144.6%），Terreno Realty Corp同比增速更快（32.6% vs -5.9%），过去两年Terreno Realty Corp的营收复合增速更高（27.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Terreno Realty Corp是一家上市房地产投资信托公司，专注于持有、运营及收购优质工业地产资产，旗下资产组合主要包括位于美国高需求沿海都会区的配送仓库与物流设施，服务电商、最后一公里配送、零售供应链等领域的租户。
APLS vs TRNO — 直观对比
营收规模更大
APLS
是对方的1.5倍
$137.5M
营收增速更快
TRNO
高出38.5%
-5.9%
净利率更高
TRNO
高出144.6%
-29.5%
两年增速更快
TRNO
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $137.5M |
| 净利润 | $-59.0M | $158.2M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 115.1% |
| 营收同比 | -5.9% | 32.6% |
| 净利润同比 | -62.2% | 107.9% |
| 每股收益（稀释后） | $-0.40 | $1.54 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTRNO
| Q4 25 | $199.9M | $137.5M | ||
| Q3 25 | $458.6M | $116.2M | ||
| Q2 25 | $178.5M | $112.2M | ||
| Q1 25 | $166.8M | $110.4M | ||
| Q4 24 | $212.5M | $103.7M | ||
| Q3 24 | $196.8M | $99.6M | ||
| Q2 24 | $199.7M | $94.2M | ||
| Q1 24 | $172.3M | $85.0M |
净利润APLSTRNO
| Q4 25 | $-59.0M | $158.2M | ||
| Q3 25 | $215.7M | $103.4M | ||
| Q2 25 | $-42.2M | $93.3M | ||
| Q1 25 | $-92.2M | $48.1M | ||
| Q4 24 | $-36.4M | $76.1M | ||
| Q3 24 | $-57.4M | $36.6M | ||
| Q2 24 | $-37.7M | $35.7M | ||
| Q1 24 | $-66.4M | $36.1M |
营业利润率APLSTRNO
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — | ||
| Q1 24 | -36.0% | — |
净利率APLSTRNO
| Q4 25 | -29.5% | 115.1% | ||
| Q3 25 | 47.0% | 88.9% | ||
| Q2 25 | -23.6% | 83.1% | ||
| Q1 25 | -55.3% | 43.6% | ||
| Q4 24 | -17.1% | 73.4% | ||
| Q3 24 | -29.2% | 36.8% | ||
| Q2 24 | -18.9% | 37.9% | ||
| Q1 24 | -38.5% | 42.4% |
每股收益（稀释后）APLSTRNO
| Q4 25 | $-0.40 | $1.54 | ||
| Q3 25 | $1.67 | $1.00 | ||
| Q2 25 | $-0.33 | $0.90 | ||
| Q1 25 | $-0.74 | $0.47 | ||
| Q4 24 | $-0.30 | $0.78 | ||
| Q3 24 | $-0.46 | $0.37 | ||
| Q2 24 | $-0.30 | $0.37 | ||
| Q1 24 | $-0.54 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $25.0M |
| 总债务越低越好 | — | $943.3M |
| 股东权益账面价值 | $370.1M | $4.1B |
| 总资产 | $1.1B | $5.4B |
| 负债/权益比越低杠杆越低 | — | 0.23× |
8季度趋势，按日历期对齐
现金及短期投资APLSTRNO
| Q4 25 | $466.2M | $25.0M | ||
| Q3 25 | $479.2M | $26.2M | ||
| Q2 25 | $370.0M | $128.4M | ||
| Q1 25 | $358.4M | $156.5M | ||
| Q4 24 | $411.3M | $18.1M | ||
| Q3 24 | $396.9M | $243.7M | ||
| Q2 24 | $360.1M | $182.0M | ||
| Q1 24 | $325.9M | $649.6M |
总债务APLSTRNO
| Q4 25 | — | $943.3M | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $742.4M | ||
| Q1 25 | — | $741.9M | ||
| Q4 24 | — | $823.4M | ||
| Q3 24 | — | $672.2M | ||
| Q2 24 | — | $772.0M | ||
| Q1 24 | $93.1M | $771.8M |
股东权益APLSTRNO
| Q4 25 | $370.1M | $4.1B | ||
| Q3 25 | $401.2M | $4.0B | ||
| Q2 25 | $156.3M | $3.9B | ||
| Q1 25 | $164.2M | $3.9B | ||
| Q4 24 | $228.5M | $3.7B | ||
| Q3 24 | $237.1M | $3.6B | ||
| Q2 24 | $264.3M | $3.4B | ||
| Q1 24 | $266.7M | $3.4B |
总资产APLSTRNO
| Q4 25 | $1.1B | $5.4B | ||
| Q3 25 | $1.1B | $5.3B | ||
| Q2 25 | $821.4M | $5.0B | ||
| Q1 25 | $807.3M | $4.9B | ||
| Q4 24 | $885.1M | $4.8B | ||
| Q3 24 | $901.9M | $4.6B | ||
| Q2 24 | $904.5M | $4.5B | ||
| Q1 24 | $831.9M | $4.4B |
负债/权益比APLSTRNO
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.19× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | 0.35× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $271.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 1.72× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSTRNO
| Q4 25 | $-14.2M | $271.9M | ||
| Q3 25 | $108.5M | $79.5M | ||
| Q2 25 | $4.4M | $60.6M | ||
| Q1 25 | $-53.4M | $61.4M | ||
| Q4 24 | $19.4M | $232.7M | ||
| Q3 24 | $34.1M | $70.0M | ||
| Q2 24 | $-8.3M | $64.3M | ||
| Q1 24 | $-133.0M | $47.0M |
自由现金流APLSTRNO
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSTRNO
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSTRNO
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSTRNO
| Q4 25 | — | 1.72× | ||
| Q3 25 | 0.50× | 0.77× | ||
| Q2 25 | — | 0.65× | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 3.06× | ||
| Q3 24 | — | 1.91× | ||
| Q2 24 | — | 1.80× | ||
| Q1 24 | — | 1.30× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TRNO
| Disposal Group Disposed Of By Sale Not Discontinued Operations | $109.5M | 80% |
| Other | $23.8M | 17% |
| At Market Equity Offering Program500Million | $4.1M | 3% |
